title: Incidence, patient characteristics and predictors of aborted myocardial infarction in patients undergoing primary PCI: prospective study comparing pre- and in-hospital abciximab pretreatment.
abstract: OBJECTIVE
  This study was performed to assess the incidence, patient characteristics and predictors of aborted myocardial infarction (MI) in patients with ST-segment elevation MI (STEMI) undergoing primary percutaneous coronary intervention (PPCI).
  
  
  RESULTS
  We enrolled 179 consecutive patients with STEMI within a fixed protocol for PPCI (Leiden MISSION! project); 90 patients received abciximab bolus in the hospital (in-hospital group) and 89 patients received abciximab bolus in the ambulance (pre-hospital group). Thirty-two patients (18%) fulfilled the criteria for an aborted MI. The incidence of aborted MI was four times higher in the pre-hospital abciximab group compared to the in-hospital group (OR = 4.2, 95% CI = 1.7-10.3). The median time between symptoms onset and abciximab bolus administration was significantly shorter in the aborted MI compared to established MI patients (70 vs. 115 min, p = 0.005). Multivariable analysis identified prehospital abciximab administration as the main predictor of aborted MI (OR = 2.86, 95% CI = 1.1-7.5).
  
  
  CONCLUSIONS
  In patients with STEMI treated with PPCI, the incidence of aborted MI was 18%. Pre-hospital abciximab administration was the main predictor of aborted MI, and this effect was related to the initiation of treatment within the first two hours after symptoms onset and to the higher infarct related artery patency at presentation.
authors.affiliation: Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
authors.forename: Ayman K M
authors.initials: AK
authors.lastname: Hassan
authors.forename: J Wouter
authors.initials: JW
authors.lastname: Jukema
authors.forename: Arnoud
authors.initials: A
authors.lastname: van der Laarse
authors.forename: Hosam
authors.initials: H
authors.lastname: Hasan-Ali
authors.forename: Ron
authors.initials: R
authors.lastname: Wolterbeek
authors.forename: Frank
authors.initials: F
authors.lastname: van der Kley
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Spano
authors.forename: Douwe E
authors.initials: DE
authors.lastname: Atsma
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Schalij
mesh_terms: D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D017023:Coronary Angiography; D004334:Drug Administration Schedule; D004562:Electrocardiography; D004632:Emergency Medical Services; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D015994:Incidence; D007297:Inpatients; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D011446:Prospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab